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(∆NTCP). In the Netherlands, a national consensus has been 
reached regarding the threshold for (∆NTCP  
Finally, the potential benefits of protons can be clinically 
validated in step 4, based on external validation of the NTCP-
models when patients are treated with protons. The model-
based approach is an evidence-based methods for selection 
and validation of new radiation technologies. 
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Synopsis:  
In thoracic irradiation, the maximum radiation dose is 
restricted by the risk of radiation-induced cardiopulmonary 
damage and dysfunction limiting tumor control. 
Unfortunately, current clinical practice does not include 
preventative measures to attenuate radiation-induced lung or 
cardiac toxicity. Inhibition of the renin-angiotensin system 
(RAS) seems to be an alluring strategy for attenuating 
radiation-induced cardiopulmonary dysfunction.  
Interestingly, angiotensin-converting enzyme inhibitors (ACEi) 
have been shown to reduce the risk of radiation-induced 
respiratory dysfunction in preclinical (1) and clinical studies 
(2). More recently a study in rats showed that ACEi reduces 
respiratory dysfunction indirectly by reducing acute heart 
damage (3).  
So far, the mechanisms of the protective effect of ACEi on 
radiation-induced toxicity are not clear. Apart from their 
hypotensive action, ACEi are known to have other properties 
such as an anti-inflammatory action. Further, it has been 
suggested that the sulfhydryl group in the molecular 
structure of captopril confers in a free radical scavenger 
activity. All these effects can account in part for its 
radioprotection. Besides, it might act as an antioxidant to 
reduce inflammatory reactive oxygen species and thus 
mitigate radiation-induced toxicity.  
To conclude, ACE inhibitors have been shown to mitigate 
radiation-induced cardio-/pulmonary toxicity in (pre)clinical 
models. However, the mechanisms of action are not clear. As 
such the use of ACE inhibitors should be further evaluated as 
a strategy to reduce cardiopulmonary complications induced 
by radiotherapy to the thoracic area.  
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RI musculo-squeletic sequelae combine opposite tissular 
aspects of fibrosis and atrophy in an heterogeneous 
patchwork comprising concomitant active cellular and 
sclerotic matricial areas. Tissue remodeling follow early, 
subacute, chronic inflammatory changes, then fibrosis and 
necrosis, that provides signaling pathways through growth 
factors and their receptors.  
In medicine, clinical cure of a chronic disease is never binary 
or surgical, if exists, because of the pathologic underground 
network well-established in the tissues.  
Cure for radiation-induced (RI) late damages should be 
approach by a strategy using a hierarchical control of 
accurate protagonists. During last decades, each therapeutic 
intervention has illustrated successively one of the facets of 
this fibrotic process:  
- In seventies, STEROIDS, then non anti-inflammatory drugs, 
showed able to stop acute RIF progression and are always 
required today as the first treatment in all sequelae, while 
anti-collagenic drugs were too toxic.  
- In eighties, vascular approach revealed antithrombotic help 
in some acute aspects (HEPARIN), and interesting role of 
PENTOXIFYLLINE (speed healing) or HBO.  
- In nineties, successful clinical use of superoxide dismutase 
(SOD) allowed to bring to light reactive oxygen species (ROS) 
- fibroblasts and their related anti-oxidant strategy, then 
PENTOXIFYLLINE-VITAMIN E (PE) combination. The fibrotic 
clinical regression was slow but measurable, followed by 
convincing “preclinical” studies (histological reversion, in 
vitro modulation): first cases of fibrotic clinical cure [1,2].  
- Then anticytokines (TGFβ, CTGF, …).  
- After 2000, adding clodronate, in a PENTOCLO combination, 
allowed speeder and durable clinical RI responses, 
highlighting its anti-macrophagic effect on bone necrosis : 
first cases of osteoradionecrosis clinical cure [3]. However, 
therapeutic range of these drugs is tight, related to 
bisphosphonate absence of specificity and the bivalent 
macrophagic action (M1/M2 populations).  
Clinical cure is a difficult art: it should take in account all 
these several facets. In the future, controlled trials and 
preclinical studies are necessary to identify best antifibrotic 
agents (phenotypic revesion of deficient cells), and organ 
specific targeted drugs and/or stem cell therapy (compensate 
tissular depletion after cell death), to obtain regular clinical 
cure if any.  
REF [1] Delanian et al. Kinetics of response to long-term 
treatment combining pentoxifylline - tocopherol in patients 
with superficial radiation-induced fibrosis. J Clin Oncol 
2005, 23, 8570. [2] Lefaix et al. Striking regression of 
subcutaneous fibrosis induced by high doses of gamma-rays 
using a combination of pentoxifylline and tocopherol: an 
experimental study. IJROBP 1999, 43, 839. [3] Delanian et al. 
Complete restoration of refractory mandibular 
osteoradionecrosis by prolonged treatment with a 
pentoxifylline-tocopherol-clodronate combination 
(PENTOCLO): phase II trial. IJROBP 2011, 80: 832. 
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Radiation-induced fibrosis is a delayed complication of 
radiotherapy often associated with chronic inflammatory 
process and macrophage infiltration. Nowadays, macrophages 
are suggested to be important cellular contributors to 
fibrogenic process, but their implication in the context of RIF 
is not well known. 
To investigate the role of macrophages in RIF we have used a 
classical experimental model of lung fibrosis developed in 
C57Bl/6 mice after 16Gy thorax-IR. We then profiled both 
alveolar macrophages (AM) and interstitial macrophages (IM) 
during the various steps of the fibrogenic process. 
We confirmed the fact that total lung irradiation at 16Gy (IR) 
induces an interstitial fibrosis associated with delayed 
recruitment of pulmonary macrophages. We found a transient 
depletion of AM associated with cytokine secretion during the 
acute post-IR phase (15 days), followed by an active 
repopulation and an enhanced number of AM during the late 
post-IR phase (20 weeks). Interestingly, AM were mostly 
recruited from the bone marrow and exhibit a hybrid 
polarization (M1/M2) associated with up-regulation of Th1 
and Th2 cytokines. The number of M2-polarized IM 
significantly increased during the late time points after 
irradiation and a down-regulation of Th1 cytokine was 
measured in tissue lysate. These results suggest a differential 
contribution of hybrid AM vsM2-IM to fibrogenesis. 
Interestingly, in contrast to activated hybrid AM, activated 
M2-IM were able to induce fibroblast activation in vitro 
mediated by an enhanced TGF-β1 expression suggesting a 
profibrotic role of M2-IM. Specific depletion of hybrid AM 
using intranasal administration of clodrosome increased 
radiation-induced fibrosis score and enhanced M2-IM 
infiltration suggesting a protective role of hybrid AM. 
These present study shows a dual and opposite contribution 
of alevolar versus intertitial macrophages in radiation-
induced fibrosis and identify M2-IM as a potential therapeutic 
target to treat radiation-induced fibrosis. 
 
Symposium: Regional nodal irradiation for breast cancer  
 
 
SP-0015  
The axilla- less surgery, more radiotherapy? 
M.I. Algara López
1Hospital de la Esperança, Radiation Oncology, Barcelona, 
Spain 
1 
 
Irradiation of lymph node areas in breast cancer patients, 
especially in early stages of the disease is a controversial 
topic. The recommendation to irradiate lymph nodes is 
clearly indicated in patients with more than three involved 
nodes. In these cases, after standard lymphadenectomy, the 
volumes to irradiate include supraclavicular fossa and axillary 
level III nodes. Until a few years ago, irradiation of axillary 
levels I and II, are reserved for cases of very large axillary 
involvement, or in patients whom lymphadenectomy was 
insufficient (less than 10 lymph nodes resected). However, 
when only 1 to 3 nodes are involved, there is no unanimity on 
the radiotherapy recommendations, despite several studies 
having show clearly a disease free survival improvement in 
irradiated patients. The Canadian trial NCIC-CTG MA20, 
including high risk patients, most of them with 1 to 3 
involved nodes, showed that local irradiation with regional 
lymph node irradiation improved disease-free survival, both 
loco-regional and distant disease control. The EORTC trial 
also demonstrates the same findings: regional irradiation in 
breast cancer patients improve even the overall survival. 
Therefore the current trend, described in international 
guidelines, lymph node irradiation is recommended for all 
patients regardless of the number of positive nodes. 
Nevertheless, the therapeutic value of axillary 
lymphadenectomy has been questioned for a long time. The 
ACOSOG Z0011 study results have caused clinical practice 
changes since many axillary dissections are being avoided. 
Even several clinical practice guidelines, including prestigious 
ones such as those of National Comprehensive Cancer 
Network, don’t recommend lymphadenectomy. The ACOSOG 
Z0011 does not exactly describe the irradiated nodal volumes 
exactly. Therefore, the nodal volumes to include in the 
irradiation treatment of early stages of breast cancer remains 
under discussion, especially without axillary 
lymphadenectomy despite involvement of sentinel lymph 
nodes. In most cases, breast irradiation with tangent fields 
implies certain “incidental” of axillary level I, and also in 
some cases the level II. For this reason, some groups have 
decided to avoid intentional irradiation of these axillary 
areas, while others advocate to irradiate them intentionally, 
without clear evidence to do that. The AMAROS trial 
demonstrated that lymph node radiotherapy obtains the same 
results as axillary dissection in node-positive patients without 
primary systemic treatment, with less morbidity. Therefore, 
it is possible to replace the surgery with radiation. The 
current situation is that some groups decide to irradiate 
lymph node in cases with positive sentinel node without 
lymphadenectomy and other groups in these cases do not 
treat the lymph node, and accept that some incidental 
irradiation will arrive by tangential fields. But, we do not 
know which patients, with positive nodes, do not require 
lymph node irradiation. It is possible that in patients with low 
axillary involvement intentional irradiation would not be 
necessary. In order to demonstrate this hypothesis, we have 
started the OPTYMAL trial (www.clinicaltrials.gov 
/ct2/show/NCT02335957?term=osna&rank=7) to investigate 
the non-inferiority of incidental versus intentional irradiation 
of axillary nodes in patients with axillary involvement of 250-
15000 copies/uL with One Step Nucleic Acid Amplification 
method (OSNA). We decided to use this method to unify the 
pathological reports. This international multicenter trial must 
help us to elucidate the necessity of node area irradiation by 
combining with reliable information about the tumor load 
involvement in axillary nodes. 
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Locoregional radiation therapy (RT) improves locoregional 
control and survival for patients treated with breast 
conserving therapy and for patients after mastectomy with 
risk factors including involved axillary lymph nodes. In the 
past, however, this treatment could be linked to an increased 
risk for late cardiovascular morbidity and mortality as a 
result of cardiac exposure to radiation. This was especially 
the case for the treatment of the internal mammary lymph 
node target volume, for which this was abandoned by many 
